AbbVie has announced that it has completed its acquisition of Capstan Therapeutics. With the completion of the acquisition, ...

AbbVie’s oncology segment generated combined revenues of $3.3 billion in the first half of 2025, rising 4.2% year over year ...

AbbVie Submits for U.S. FDA Approval of Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) ...

Intensive chemotherapy improved survival in patients with accelerated and blast phase myeloproliferative neoplasms, with ...

About VENCLEXTA® (venetoclax) VENCLEXTA (venetoclax) is a first-in-class medicine that selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein.

VENCLEXTA and other medicines may affect each other causing serious side effects. Do not start new medicines during treatment with VENCLEXTA without first talking with your healthcare provider.

About VENCLEXTA® (venetoclax) VENCLEXTA (venetoclax) is a first-in-class medicine that selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein. In some blood cancers, BCL-2 prevents ...

"This FDA submission marks a milestone for CLL treatment with the potential approval for the first oral combination regimen of VENCLEXTA and acalabrutinib for previously untreated patients with ...

AbbVie (NYSE: ABBV) announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the fixed-duration, all-oral combination regimen of ...

AbbVie (ABBV) recently submitted a Supplemental New Drug Application to the FDA for a new combination regimen targeting chronic lymphocytic leukemia, which accompanies positive Phase 3 trial ...

Over the past decade, AbbVie's shares have increased by 353.3%, or 16.3% annually, with dividends reinvested. That's ...